Search

Your search keyword '"Inst Hosp del Mar Invest Med"' showing total 3 results
Start Over Author "Inst Hosp del Mar Invest Med" Topic chemistry.chemical_compound
3 results on '"Inst Hosp del Mar Invest Med"'

1. Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort Study

Author

Lopez Montesinos, Inmaculada, Gomez-Zorrilla, Silvia, Palacios-Baena, Zaira Raquel, Prim, Nuria, Echeverria-Esnal, Daniel, Gracia, Maria Pilar, Montero, Maria Milagro, Duran-Jorda, Xavier, Sendra, Elena, Sorli, Luisa, Guerri-Fernandez, Roberto, Padilla, Eduardo, Grau, Santiago, Horcajada, Juan Pablo, PROA PSMAR grp, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, [Lopez Montesinos, Inmaculada] Univ Pompeu Fabra, Spanish Network Res Infect Dis REIPI, Inst Hosp del Mar Invest Med IMIM, Infect Dis Serv,Hosp del Mar,Infect Pathol & Anti, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Gomez-Zorrilla, Silvia] Univ Pompeu Fabra, Spanish Network Res Infect Dis REIPI, Inst Hosp del Mar Invest Med IMIM, Infect Dis Serv,Hosp del Mar,Infect Pathol & Anti, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Montero, Maria Milagro] Univ Pompeu Fabra, Spanish Network Res Infect Dis REIPI, Inst Hosp del Mar Invest Med IMIM, Infect Dis Serv,Hosp del Mar,Infect Pathol & Anti, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Sendra, Elena] Univ Pompeu Fabra, Spanish Network Res Infect Dis REIPI, Inst Hosp del Mar Invest Med IMIM, Infect Dis Serv,Hosp del Mar,Infect Pathol & Anti, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Sorli, Luisa] Univ Pompeu Fabra, Spanish Network Res Infect Dis REIPI, Inst Hosp del Mar Invest Med IMIM, Infect Dis Serv,Hosp del Mar,Infect Pathol & Anti, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Guerri-Fernandez, Roberto] Univ Pompeu Fabra, Spanish Network Res Infect Dis REIPI, Inst Hosp del Mar Invest Med IMIM, Infect Dis Serv,Hosp del Mar,Infect Pathol & Anti, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Horcajada, Juan Pablo] Univ Pompeu Fabra, Spanish Network Res Infect Dis REIPI, Inst Hosp del Mar Invest Med IMIM, Infect Dis Serv,Hosp del Mar,Infect Pathol & Anti, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Palacios-Baena, Zaira Raquel] Univ Hosp Virgen Macarena, Inst Biomed Seville IBIS, Unit Infect Dis & Clin Microbiol, Ave Dr Fedriani 3, Seville 41009, Spain, [Prim, Nuria] Lab Referencia Catalunya, Microbiol Serv, Carrer Selva 10, El El Prat De Llobregat 08820, Barcelona, Spain, [Padilla, Eduardo] Lab Referencia Catalunya, Microbiol Serv, Carrer Selva 10, El El Prat De Llobregat 08820, Barcelona, Spain, [Echeverria-Esnal, Daniel] Univ Pompeu Fabra, Inst Hosp del Mar Invest Med IMIM, Hosp del Mar, Pharm Serv,Infect Pathol & Antimicrobials Res Grp, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Grau, Santiago] Univ Pompeu Fabra, Inst Hosp del Mar Invest Med IMIM, Hosp del Mar, Pharm Serv,Infect Pathol & Antimicrobials Res Grp, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Gracia, Maria Pilar] Univ Pompeu Fabra, Inst Hosp del Mar Invest Med IMIM, Hosp del Mar, Intens Care Unit Serv, Passeig Maritim Barceloneta 25,29, Barcelona 08003, Spain, [Duran-Jorda, Xavier] Inst Hosp del Mar Invest Med IMIM, Methodol & Biostat Support Unit, Carrer Dr Aiguader 88, Barcelona 08003, Spain, Ministerio de Economia y competitividad of Spain, Instituto de Salud Carlos III, European Development Regional Fund 'A way to achieve Europe' (ERDF), Operative program Intelligent Growth 2014-2020, and Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

Subjects
Microbiology (medical), medicine.medical_specialty, medicine.drug_class, Cefepime, Antibiotics, Ceftazidime, Aztreonam, Antimicrobial stewardship, chemistry.chemical_compound, Sepsis, Internal medicine, Medicine, Extensively drug-resistant Pseudomonas aeruginosa, Mortality, Amikacin, business.industry, Colistin, medicine.disease, Urinary tract infections, Infectious Diseases, chemistry, Bacteremia, SOFA score, business, medicine.drug
Abstract

[Introduction] Extensively drug-resistant (XDR) Pseudomonas aeruginosa (PA) infections are difficult to treat. We aimed to compare aminoglycosides or polymyxin monotherapy versus other antibiotic regimens (carbapenems, aztreonam, ceftazidime, cefepime, ceftolozane-tazobactam, or ceftazidime-avibactam) in complicated urinary tract infections (cUTI) caused by XDR-PA., [Methods] Study performed at a tertiary-care hospital from 2010 to 2019. All consecutive adult patients with XDR-PA urine cultures and diagnosed with cUTI were retrospectively reviewed. XDR phenotype was defined according to Magiorakos et al. A propensity score was used as a covariate in multivariate analyses and for matching. Primary outcome was early clinical failure and at end of treatment (EOT). Main secondary outcomes were 30- and 90-day mortality, microbiological clearance, and antibiotic-related side effects., [Results] Of the 465 episodes screened, 101 were included, 48% were treated with aminoglycoside or colistin monotherapy. Most XDR-PA were susceptible to colistin (100%) and amikacin (43%). Patients treated with antibiotic regimens other than aminoglycosides or polymyxin monotherapy were more likely to have hematologic malignancy (p, [Conclusions] Aminoglycosides or polymyxin monotherapy showed good efficacy and safety profile in treating cUTI caused by XDR-PA. These results may be useful for antibiotic stewardship activities., This work was supported by the Ministerio de Economia y competitividad of Spain, Instituto de Salud Carlos III [grant number PI17/00251 to J.P.H.], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (ERDF), Operative program Intelligent Growth 2014–2020. Silvia Gómez-Zorrilla has received a research grant from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) to support her research. The journal’s Rapid Service Fee was funded by the authors.

Published
2022

2. Genomics And Susceptibility Profiles Of Extensively Drug-resistant Pseudomonas Aeruginosa Isolates From Spain

Author

Ester del Barrio-Tofiño, Luisa Sorlí, José Antonio Martínez, Concepción Segura, Fe Tubau, Antonio Oliver, Luis Martínez-Martínez, Natividad Benito, Alba Rivera, Gabriel Cabot, Elena Resino-Foz, Juan Pablo Horcajada, Raquel Durá-Navarro, Laura Zamorano, María Milagro Montero, Cristina Labayru-Echverria, Silvia Gómez-Zorrilla, Marta Fernández-Martínez, Ignacio Ayestarán, Esther Viedma, Carlos Dueñas, Izaskun Alejo-Cancho, Carla López-Causapé, Claudia González-Rico, Nuria Tormo, [del Barrio-Tofino, Ester] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Dept Microbiol, Intens Care Unit, Palma De Mallorca, Spain, [Lopez-Causape, Carla] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Dept Microbiol, Intens Care Unit, Palma De Mallorca, Spain, [Cabot, Gabriel] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Dept Microbiol, Intens Care Unit, Palma De Mallorca, Spain, [Ayestaran, Ignacio] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Dept Microbiol, Intens Care Unit, Palma De Mallorca, Spain, [Zamorano, Laura] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Dept Microbiol, Intens Care Unit, Palma De Mallorca, Spain, [Oliver, Antonio] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Dept Microbiol, Intens Care Unit, Palma De Mallorca, Spain, [del Barrio-Tofino, Ester] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Unidad Invest, Palma De Mallorca, Spain, [Lopez-Causape, Carla] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Unidad Invest, Palma De Mallorca, Spain, [Cabot, Gabriel] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Unidad Invest, Palma De Mallorca, Spain, [Ayestaran, Ignacio] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Unidad Invest, Palma De Mallorca, Spain, [Zamorano, Laura] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Unidad Invest, Palma De Mallorca, Spain, [Oliver, Antonio] Hosp Univ Son Espases, Inst Invest Illes Balears IdISBa, Unidad Invest, Palma De Mallorca, Spain, [Rivera, Alba] Hosp Santa Creu & Sant Pau, Dept Microbiol & Infect Dis, Barcelona, Spain, [Benito, Natividad] Hosp Santa Creu & Sant Pau, Dept Microbiol & Infect Dis, Barcelona, Spain, [Segura, Concepcion] Hosp del Mar, Lab Referencia Catalunya, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Milagro Montero, Maria] Hosp del Mar, Lab Referencia Catalunya, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Sorli, Luisa] Hosp del Mar, Lab Referencia Catalunya, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Pablo Horcajada, Juan] Hosp del Mar, Lab Referencia Catalunya, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Segura, Concepcion] Hosp del Mar, Dept Infect Dis, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Milagro Montero, Maria] Hosp del Mar, Dept Infect Dis, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Sorli, Luisa] Hosp del Mar, Dept Infect Dis, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Pablo Horcajada, Juan] Hosp del Mar, Dept Infect Dis, Infect Pathol & Antimicrobial Res Grp IPAR, Inst Hosp del Mar Invest Med IMIM, Barcelona, Spain, [Tubau, Fe] Hosp Univ Bellvitge, Dept Microbiol & Infect Dis, Barcelona, Spain, [Gomez-Zorrilla, Silvia] Hosp Univ Bellvitge, Dept Microbiol & Infect Dis, Barcelona, Spain, [Tormo, Nuria] Consorcio Hosp Gen Univ Valencia, Dept Microbiol & Infect Dis, Valencia, Spain, [Dura-Navarro, Raquel] Consorcio Hosp Gen Univ Valencia, Dept Microbiol & Infect Dis, Valencia, Spain, [Viedma, Esther] Hosp Univ 12 Octubre, Dept Microbiol & Infect Dis, Madrid, Spain, [Resino-Foz, Elena] Hosp Univ 12 Octubre, Dept Microbiol & Infect Dis, Madrid, Spain, [Fernandez-Martinez, Marta] Hosp Univ Marques de Valdecilla, Inst Invest Valdecilla IDIVAL, Dept Microbiol & Infect Dis, Santander, Spain, [Gonzalez-Rico, Claudia] Hosp Univ Marques de Valdecilla, Inst Invest Valdecilla IDIVAL, Dept Microbiol & Infect Dis, Santander, Spain, [Alejo-Cancho, Izaskun] Hosp Univ Clin, Dept Microbiol & Infect Dis, Barcelona, Spain, [Antonio Martinez, Jose] Hosp Univ Clin, Dept Microbiol & Infect Dis, Barcelona, Spain, [Labayru-Echverria, Cristina] Hosp Univ Burgos, Dept Microbiol & Infect Dis, Burgos, Spain, [Duenas, Carlos] Hosp Univ Burgos, Dept Microbiol & Infect Dis, Burgos, Spain, [Martinez-Martinez, Luis] Univ Cordoba, Hosp Univ Reina Sofia, Dept Microbiol, Unit Microbiol, Cordoba, Spain, [Martinez-Martinez, Luis] Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain, Plan Nacional de I+D+i, Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases, and European Development Regional Fund (ERDF)

Subjects
0301 basic medicine, Imipenem, Ceftazidime, Penicillanic Acid, Aztreonam, Drug resistance, medicine.disease_cause, Antimicrobial resistance, chemistry.chemical_compound, polycyclic compounds, Pharmacology (medical), Aminoglycoside resistance, Molecular Epidemiology, extensively drug resistant, Beta-lactam resistance, Ceftolozane-tazobactam, Broth microdilution, 3. Good health, Anti-Bacterial Agents, Infectious Diseases, high-risk clones, Amikacin, whole-genome sequencing, Molecular epidemiology, Pseudomonas aeruginosa, Erratum, Convergent evolution, Mutations, medicine.drug, Fluoroquinolones, Field gel-electrophoresis, Tazobactam, Carbapenem resistance, Cxa-101 fr264205, Epidemiologia molecular, 030106 microbiology, Microbial Sensitivity Tests, Biology, beta-Lactam Resistance, beta-Lactamases, Microbiology, 03 medical and health sciences, Polymyxin resistance, Bacterial Proteins, Pseudomonas, Drug Resistance, Bacterial, medicine, Humans, Pseudomonas Infections, Polymyxins, Pharmacology, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, Cephalosporins, Aminoglycosides, chemistry, Spain
Abstract

This study assessed the molecular epidemiology, resistance mechanisms, and susceptibility profiles of a collection of 150 extensively drug-resistant (XDR) Pseudomonas aeruginosa clinical isolates obtained from a 2015 Spanish multicenter study, with a particular focus on resistome analysis in relation to ceftolozane-tazobactam susceptibility. Broth microdilution MICs revealed that nearly all (>95%) of the isolates were nonsusceptible to piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, and ciprofloxacin. Most of them were also resistant to tobramycin (77%), whereas nonsusceptibility rates were lower for ceftolozane-tazobactam (31%), amikacin (7%), and colistin (2%). Pulsed-field gel electrophoresis–multilocus sequence typing (PFGE-MLST) analysis revealed that nearly all of the isolates belonged to previously described high-risk clones. Sequence type 175 (ST175) was detected in all 9 participating hospitals and accounted for 68% ( n = 101) of the XDR isolates, distantly followed by ST244 ( n = 16), ST253 ( n = 12), ST235 ( n = 8), and ST111 ( n = 2), which were detected only in 1 to 2 hospitals. Through phenotypic and molecular methods, the presence of horizontally acquired carbapenemases was detected in 21% of the isolates, mostly VIM (17%) and GES enzymes (4%). At least two representative isolates from each clone and hospital ( n = 44) were fully sequenced on an Illumina MiSeq. Classical mutational mechanisms, such as those leading to the overexpression of the β-lactamase AmpC or efflux pumps, OprD inactivation, and/or quinolone resistance-determining regions (QRDR) mutations, were confirmed in most isolates and correlated well with the resistance phenotypes in the absence of horizontally acquired determinants. Ceftolozane-tazobactam resistance was not detected in carbapenemase-negative isolates, in agreement with sequencing data showing the absence of ampC mutations. The unique set of mutations responsible for the XDR phenotype of ST175 clone documented 7 years earlier were found to be conserved, denoting the long-term persistence of this specific XDR lineage in Spanish hospitals. Finally, other potentially relevant mutations were evidenced, including those in penicillin-binding protein 3 (PBP3), which is involved in β-lactam (including ceftolozane-tazobactam) resistance, and FusA1, which is linked to aminoglycoside resistance.

Published
2017

3. RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein

Author

Elisabeth Figuerola, Carlos Pardo-Pastor, Jaume Mora, Enrique de Álava, Lourdes Hontecillas-Prieto, Carmen de Torres, Angel M. Carcaboso, Eva Rodríguez, Inmaculada Hernández-Muñoz, Oscar M. Tirado, Sara Sanchez-Molina, Ana I. Fernández-Mariño, José M. Fernández-Fernández, Daniel J. García-Domínguez, Maria I. Bahamonde, Cinzia Lavarino, Instituto de Salud Carlos III, Generalitat de Catalunya, European Commission, Ministerio de Economía y Competitividad (España), Asociación Española Contra el Cáncer, Asociación Pablo Ugarte, [Hernandez-Munoz, Inmaculada] Fdn Inst Hosp del Mar Invest Med FIMIM, E-08003 Barcelona, Spain, [Figuerola, Elisabeth] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain, [Sanchez-Molina, Sara] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain, [Rodriguez, Eva] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain, [Lavarino, Cinzia] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain, [Carcaboso, Angel M.] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain, [de Torres, Carmen] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain, [Mora, Jaume] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain, [Isabel Fernandez-Marino, Ana] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain, [Pardo-Pastor, Carlos] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain, [Isabel Bahamonde, Maria] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain, [Fernandez-Fernandez, Jose M.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain, [Garcia-Dominguez, Daniel J.] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS,Dept Pediat Hematol & On, E-41013 Seville, Spain, [Hontecillas-Prieto, Lourdes] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS,Dept Pediat Hematol & On, E-41013 Seville, Spain, [de Alava, Enrique] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS,Dept Pediat Hematol & On, E-41013 Seville, Spain, [Tirado, Oscar M.] Inst Invest Biomed Bellvitge IDIBELL, Lab Oncol Mol, Sarcoma Res Grp, Barcelona 08908, Spain, [Isabel Fernandez-Marino, Ana] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosci & Biomol Chem, Madison, WI 53705 USA, Xarxa de Bancs de Tumors de Catalunya, Pla Director d'Oncologia de Catalunya, ISCIII-FEDER, Ministerio de Economia y Competitividad (MEC), FEDER Funds, Asociacion Espanola Contra el Cancer (AECC), AECC, MEC-FEDER, European FP7 Projects EuroSARC (FP7HEALTH-two-stage), Euroewing, Fundacion Memoria de DM Solorzano Barruso, Fundacion Cris contra el Cancer, Pablo Ugarte Foundation, Fundacion M. Garcia Estrada, and European FP7 projects (FP7) under a Marie Curie International Reintegration Grant

Subjects
0301 basic medicine, P50, Cellular differentiation, Neuroectodermal tumors, RING1B, Bone Neoplasms, Sarcoma, Ewing, Genomic landscape, NF-κB, 03 medical and health sciences, chemistry.chemical_compound, Sarcoma -- Aspectes genètics, Fibroblast-growth-factor, In-vivo, voltage-gated sodium channel, Voltage-gated sodium channel, Tumor Cells, Cultured, Medicine, Humans, Family, FGFR/SHP2/STAT3, STAT3, Polycomb Repressive Complex 1, biology, Oncogene, business.industry, Histone h2a, Tyrosine-phosphatase, NF-kappa B, NFKB1, Stem-cells, 3. Good health, 030104 developmental biology, Oncology, chemistry, Apoptosis, NAV1.6 Voltage-Gated Sodium Channel, Cancer research, biology.protein, Marrow stromal cells, Signal transduction, Neural differentiation, business, Ewing sarcoma, Research Paper, Signal Transduction
Abstract

Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability., IHM is a Miguel Servet investigator (Instituto de Salud Carlos III, ISCIII). This work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya and by grants from ISCIII-FEDER (PS09/00973; RIC RD12/0042/0014, Red HERACLES), Ministerio de Economía y Competitividad (MEC) (SAF2012-31089 and SAF2015-69762-R), FEDER Funds and by the Asociación Española Contra el Cáncer (AECC). E.Á.’s lab is supported by the AECC, MEC-FEDER (RD12/0036/0017, PT13/0010/0056, RTC-2014-2102-1, ISCIII Sara Borrell CD06/00001, PI12/03102, PI14/01466), the European FP7 Projects EuroSARC (FP7-HEALTH-2011-two-stage, Project 278742 EUROSARC), Euroewing (FP7-HEALTH.2013.2.4.1-1, Project 602856), Fundación Memoria de DM Solorzano Barruso, Fundación Cris contra el Cáncer, Pablo Ugarte Foundation, and Fundación M. García Estrada. O.M.T. is funded by ISCIII-FEDER (CES12/021) and the AECC. AMC is funded by the European FP7 projects (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG-08- GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group at the Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, is supported by the AECC and the generous donations from Pablo Ugarte Foundation.

Catalog

Books, media, physical & digital resources
See catalog results